TITLE

Perspective of Small-Molecule AdipoR Agonist for Type 2 Diabetes and Short Life in Obesity

AUTHOR(S)
Okada-Iwabu, Miki; Kadowaki, Takashi; Iwabi, Masato; Yamauchi, Toshimasa; Ueki, Kohjiro
PUB. DATE
October 2015
SOURCE
Diabetes & Metabolism Journal;Oct2015, Vol. 39 Issue 5, p363
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Obesity associated with unhealthy diet and lack of exercise is shown to contribute to the onset and/or aggravation of the metabolic syndrome and diabetes, thus placing affected individuals at increased risk of cardiovascular disease and cancer. Plasma adiponectin levels are decreased in obesity, which causes insulin resistance and diabetes. Therefore, we identified adiponectin receptors (AdipoRs) as the therapeutic target. It was suggested that, similarly to caloric restriction and exercise, activation of the Adipo s may have the potential not only to improve lifestyle-related diseases but to contribute to prolonged the shortened lifespan on a high caloric unhealthy diet. To this end, we have identified "AdipoRon" as an adiponectin receptor agonist. Indeed, Adipo- Ron ameliorated diabetes associated with obesity as well as to increase exercise endurance, thus prolonging shortened lifespan of obese mice fed on a high fat diet. Additionally, we have recently determined the crystal structures of the human AdipoRs The seven- transmembrane helices of AdipoRs are structurally distinct from those of G-protein coupled receptors. It is expected that these findings will contribute not only to the elucidation of the AdipoR-related signal transduction but to the development and optimization of AdipoR-targeted therapeutics for obesity-related diseases such as diabetes.
ACCESSION #
110954038

 

Related Articles

  • A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Okada-Iwabu, Miki; Yamauchi, Toshimasa; Iwabu, Masato; Honma, Teruki; Hamagami, Ken-ichi; Matsuda, Koichi; Yamaguchi, Mamiko; Tanabe, Hiroaki; Kimura-Someya, Tomomi; Shirouzu, Mikako; Ogata, Hitomi; Tokuyama, Kumpei; Ueki, Kohjiro; Nagano, Tetsuo; Tanaka, Akiko; Yokoyama, Shigeyuki; Kadowaki, Takashi // Nature;11/28/2013, Vol. 503 Issue 7477, p493 

    Adiponectin secreted from adipocytes binds to adiponectin receptors AdipoR1 and AdipoR2, and exerts antidiabetic effects via activation of AMPK and PPAR-α pathways, respectively. Levels of adiponectin in plasma are reduced in obesity, which causes insulin resistance and type 2 diabetes. Thus,...

  • Strong evidence of sexual dimorphic effect of adiposity excess on insulin sensitivity. Marucci, Antonella; Menzaghi, Claudia; Copetti, Massimilano; Vinciguerra, Federica; Baratta, Roberto; Salvemini, Lucia; Morini, Eleonora; Frittitta, Lucia; Paola, Rosa; Trischitta, Vincenzo // Acta Diabetologica;Oct2015, Vol. 52 Issue 5, p991 

    Aims: Our aims were to investigate in several large samples, with a wide range of adiposity, whether: (1) the effect of BMI on insulin sensitivity is different between sexes; (2) also waist circumference plays a sex-specific role on insulin sensitivity; and (3) serum adiponectin and resistin are...

  • Voltammetry of Adiponectin and its Interactions with Collagen on a Carbon Paste Electrode at Femtogram Level. Sobrova, Pavlina; Ryvolova, Marketa; Huska, Dalibor; Hubalek, Jaromir; Provaznik, Ivo; Adam, Vojtech; Kizek, Rene // International Journal of Electrochemical Science;Jan2012, Vol. 7 Issue 1, p1 

    Adiponectin, the most abundant protein secreted by white adipose tissue, is known for its involvement in obesity-related disorders such as insulin resistance, type 2 diabetes mellitus and atherosclerosis. Besides its well-known insulin-sensitizing, anti-inflammatory and antiatherosclerotic...

  • Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis. Xin Liu; Peng Men; Yuhui Wang; Suodi Zhai; Liu, George // Lipids in Health & Disease;11/23/2016, Vol. 15, p1 

    Background: Adiponectin, an adipose-specific protein, is negatively correlated with pro-atherogenic low-density lipoprotein cholesterol (LDL-C) and other cardiovascular risk factors such as insulin resistance. Therefore, low levels of adiponectin are associated with a higher risk for diabetes...

  • In this issue.  // Clinical Pharmacology & Therapeutics;May2007, Vol. 81 Issue 5, p613 

    The article discusses various reports published within the issue, including one on state-of-the-art treatment for diabetes and another on the treatment of obesity through lifestyle modification.

  • Innovation and Improvement in the Treatment of Obesity and Diabetes. Ryder, S. W. // Clinical Pharmacology & Therapeutics;May2007, Vol. 81 Issue 5, p615 

    The article discusses various reports published within the issue, including one on potential new targets for obesity pharmacotherapy,and another on development and use of treatments for the prevention of diabetes.

  • DiscoveryBioMed Inc. Garners Funding from the National Institutes of Health to Support a Metabolic Diseases Drug Discovery Program.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that the National Institute of Health in the U.S. has offered research grant to DiscoveryBioMed Inc. for supporting the metabolic diseases drug discovery program. It mentions that the new drug increases the secretion of adiponectin from human adipocytes to prevent...

  • Powerful antibody-based strategy suggests a new therapeutic approach to diabetes and obesity.  // Biomedical Market Newsletter;9/30/2011, Vol. 21, p18 

    The article focuses on the powerful antibody-based strategy devised by a team at Cold Spring Harbor Laboratory (CSHL) in the U.S. as a therapeutic approach to diabetes and obesity.

  • Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Scislowski, P W D; Tozzo, E; Zhang, Y; Phaneuf, S; Prevelige, R; Cincotta, A H // International Journal of Obesity & Related Metabolic Disorders;Apr1999, Vol. 23 Issue 4, p425 

    OBJECTIVE: We previously reported that a two week treatment with SKF 38393 (SKF, a dopamine D1 receptor agonist), plus bromocriptine (BC, a dopamine D2 receptor agonist) acted synergistically to normalize hyperphagia, body fat, hyperglycaemia and hyperlipidaemia in ob/ob mice. The present study...

Share

Other Topics